Sanofi: UBS maintains buy rating, adjusts target price
(CercleFinance.com) - UBS reinstates its "buy" rating on the Sanofi, having nudged up its target price from 99 euros to 101 euros, which suggests upside potential of 25%, after the French healthcare group's recent CMD.
"Consensus, and we, saw general medicines as declining... but there is an implied mid single digit consensus sales upgrade at group level in 2025," the broker summarises.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"Consensus, and we, saw general medicines as declining... but there is an implied mid single digit consensus sales upgrade at group level in 2025," the broker summarises.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.